Abstract
Pneumocystis jirovecii is an opportunistic (fungal) pathogen, causing live threatening pulmonary infections in immunosuppressed patients. The diagnosis is based on clinical symptoms (fever, progressive dyspnea, dry cough), radiological findings (diffuse bilateral intestinal infiltrates), and laboratory abnormalities (hypercapnia, elevated lactate dehydrogenase, elevated (1-3)-ß-D-Glucan). Because these signs are more or less unspecific, the laboratory detection of the pathogen is essential. Since the organism is not cultivable on artificial media the diagnosis is based on the microscopic detection of cysts or trophozoites in deep respiratory material. Microscopic methods are replaced more and more by PCR systems. Because of a high incidence of colonization in asymptomatic individuals, results of quantitative assays are more helpful for clinicians than those of qualitative tests. First choice for prophylaxis and treatment is trimethoprim/sulfamethoxazole.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC (2012) Hidden killers: human fungal infections. Sci Transl Med 4:165rv13
Durand-Joly I, Aliouat EM, Recourt C, Guyot K, François N, Wauquier M, Camus D, Dei-Cas E (2002) Pneumocystis carinii f. sp. hominis is not infectious for SCID mice. J Clin Microbiol 40:1862–1865
Aliouat-Denis C-M, Chabé M, Demanche C, Aliouat EM, Viscogliosi E, Guillot J, Delhaes L, Dei-Cas E (2008) Pneumocystis species, coevolution and pathogenic power. Infect Genet Evol 8:708–726
Aliouat-Denis C-M, Martinez A, Aliouat EM, Pottier M, Gantois N, Dei-Cas E (2009) The Pneumocystis life cycle. Mem Inst Oswaldo Cruz 104:419–426
Ma L, Huang D-W, Cuomo CA, Sykes S, Fantoni G, Das B, Sherman BT, Yang J, Huber C, Xia J, Davey E, Kutty G, Bishop L, Sassi M, Lempicki RA, Kovacs JA (2013) Sequencing and characterization of the complete mitochondrial genomes of three Pneumocystis species provide new insights into divergence between human and rodent Pneumocystis. FASEB J 27:1962–1972
Stringer JR, Beard CB, Miller RF (2009) Spelling Pneumocystis jirovecii. Emerg Infect Dis 15:506
Chabé M, Aliouat-Denis C-M, Delhaes L, Aliouat EM, Viscogiosi E, Dei-Cas E (2011) Pneumocystis: from a doubtful unique entity to a group of highly diversified fungal species. FEMS Yeast Res 11:2–17
Kelly MN, Shellito JD (2010) Current understanding of Pneumocystis immunology. Future Microbiol 5:43–65
Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, Lynch K, Brubaker R, Walzer PD (2010) Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS ONE 5:e8524
Martinez A, Halliez MCM, Aliouat EM, Chabé M, Standaert-Vitse A, Fréalle E, Gantois N, Pottier M, Pinon A, Dei-Cas E, Aliouat-Denis C-M (2013) Growth and airborne transmission of cell-sorted life cycle stages of Pneumocystis carinii. PLoS ONE 8:e79958
Calderón EJ (2009) Epidemiology of Pneumocystis infection in humans. J Mycol Méd 19:270–275
Roux A, Gonzales F, Roux M, Mehrad M, Menotti J, Zahar J-R, Tadros V-X, Azoulay E, Brillet P-Y, Vincent F (2014) Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Méd Mal Infect 44:185–198
Maini R, Henderson KL, Sheridan EA, Lamagni T, Nichols G, Delpech V, Phin N (2013) Increasing Pneumocystis pneumonia, England, UK, 2000–2010. Emerg Infect Dis 19:386–392
Ponce CA, Gallo M, Bustamante R, Vargas SL (2010) Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 50:347–353
Morris A, Wei K, Afshar K, Huang L (2008) Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis 197:10–17
Vargas SL, Ponce CA, Gallo M, Pérez F, Astorga J-F, Bustamante R, Chabé M, Durand-Joly I, Iturra P, Miller RF, Aliouat EL, Dei-Cas E (2013) Near-universal prevalence of Pneumocystis and associated Increase in mucus in the lungs of infants with sudden unexpected death. Clin Infect Dis 56:171–179
Fritsche C, Ghanem H, Koball S, Mueller-Hilke B, Reisinger EC (2017) High Pneumocystis jirovecii colonization rate among haemodialysis patients. Infect Dis 49:132–136
Fritzsche C, Riebold D, Fuehrer A, Mitzner A, Klammt S, Mueller-Hilke B, Reisinger EC (2013) Pneumocystis jirovecii colonization among renal transplant recipients. Nephrology 18:382–387
Morris A, Netravali M, Kling HM, Shipley T, Ross T, Sciurba FC, Norris KA (2008) Relationship of Pneumocystis antibody response to severity of chronic obstructive pulmonary disease. Clin Infect Dis 47:e64–e68
Green HD, Bright-Thomas RJ, Mutton KJ, Guiver M, Jones AM (2016) Increased prevalence of Pneumocystis jirovecii colonization in acute pulmonary exacerbations of cystic fibrosis. J Infect 73:1–7
Yiannakis EP, Boswell TC (2016) Systematic review of outbreaks of Pneumocystis jirovecii pneumonia: evidence that P. jirovecii is a transmissible organism and the implications for healthcare infection control. J Hosp Infect 93:1–8
Siegel JD, Rhinehart E, Jackson M, Chiarello L; The Healthcare Infection Control Practices Advisory Committee (2007) Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. http://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf
LeGal S, Pougnet L, Damiani C, Fréalle E, Guéguen P, Virmaux M, Ansart S, Jaffuel S, Couturaud F, Delluc A, Tonnelier J-M, Castellant P, Le Meur Y, Le Floch G, Todet A, Menotti J, Nevez G (2015) Pneumocystis jirovecii in the air surrounding patients with Pneumocystis pulmonary colonization. Diagn Microbiol Infect Dis 82:137–142
Fong S, Daly KR, Tipirneni R, Jarlsberg LG, Djawe K, Koch JV, Swartzman A, Roth B, Walzer PD, Huang L (2013) Antibody responses against Pneumocystis jirovecii in health care workers over time. Emerg Infect Dis 19:1612–1619
Valade S, Azoulay E, Damiani C, Derouin F, Totet A, Menotti J (2015) Pneumocystis jirovecii airborne transmission between critically ill patients and health care workers. Intensive Care Med 41:1716–1718
Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J et al (1984) Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 100:663–671
Bienvenu AL, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S (2016) Pneumocystis pneumonia suspected in 604 non-HIV and HIV patients. Int J Infect Dis 46:11–17
Ng VL, Yajko DM, Hadley WK (1997) Extrapulmonary pneumocystosis. Clin Microbiol Rev 10:401–418
Rath P-M, Steinmann J (2014) Update on diagnosis of Pneumocystis pulmonary infections. Curr Fungal Infect Rep 8:227–234
Procop GW, Haddad S, Quinn J, Wilson ML, Henshaw NG, Reller LB, Artymyshyn RL, Katanik MT, Weinstein MP (2004) Detection of Pneumocystis jiroveci in respiratory specimens by four staining methods. J Clin Microbiol 42:3333–3335
Cruciani M, Marcati P, Malena M, Bosco O, Serpelloni G, Mengoli C (2002) Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J 20:982–989
Schildgen V, Mai S, Khalfaouri S, Lüsebrink J, Pieper M, Tillmann RL, Brockmann M, Schildgen O (2014) Pneumocystis jirovecii can be productively cultured in differentiated CuFi-8 air was cells. MBio 5:e01186–e01114
To KKW, Wong SCY, Xu T, Poon RWS, Mok K-Y, Chan JFW, Cheng VCC, Chan K-H, Hung IFN, Yuen K-Y (2013) Use of nasopharyngeal aspirate for diagnosis of Pneumocystis pneumonia. J Clin Microbiol 51:1570–1574
Sasso M, Chastang-Dumas E, Bastide S, Alonso S, Lechiche C, Bourgeois N, Lachauda L (2016) Performances of four real-time PCR assays for diagnosis of Pneumocystis jirovecii pneumonia. J Clin Microbiol 54:625–630
Louis M, Guitard J, Jodar M, Ancelle T, Magne D, Lascols O, Hennequin C (2015) Impact of HIV infection status on interpretation of quantitative PCR for detection of Pneumocystis jirovecii. J Clin Microbiol 53:3870–3875
Esteves F, Calé SS, Badura R, de Boer MG, Maltez F, Calderón EJ, van der Reijden TJ, Márquez-Martin E, Antunes F, Matos O (2015) Diagnosis of Pneumocystis pneumonia: evaluation of four serologic biomarkers. Clin Microbiol Infect 21:379.e1–379.e10
Finkelman MA (2010) Pneumocystis jirovecii infection: cell wall(1→3)-β-D-glucan biology and diagnostic utility. Crit Rev Microbiol 36:271–281
Theel ES, Doern CD (2013) ß-D-glucan testing is important for diagnosis of invasive fungal infections. J Clin Microbiol 51:3478–3483
Karageorgopoulos DE, Qu J-M, Korbila IP, Zhu J-G, Vasileiou VA, Falagas ME (2013) Accuracy of ß-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect 19:39–49
Li W-J, Guo Y-L, Liu T-J, Wang K, Kong J-L (2015) Diagnosis of pneumocystis pneumonia using serum (1-3)-β-D-glucan: a bivariate meta-analysis and systematic review. J Thorac Dis 7:2214–2225
Damiani C, Le Gal S, Da Costa C, Virmaux M, Nevez G, Totet A (2013) Combined quantification of pulmonary pneumocystis jirovecii DNA and serum (1-3)-D-glucan for differential diagnosis of Pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol 51:3380–3388
Damiani C, Le Gal S, Goin N, Di Pizio P, Da Costa C, Virmaux M, Bach V, Stéphan-Blanchard E, Nevez G, Totet A (2015) Usefulness of (1,3) ß-D-glucan detection in bronchoalveolar lavage samples in Pneumocystis pneumonia and Pneumocystis pulmonary colonization. J Mycol Méd 25:36–43
Messiaen PE, Cuyx S, Dejagere T, van der Hilst JC (2017) The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: a systematic review. Transpl Infect Dis 19:e12651
Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, Hauser PM, Lagrou K, Melchers WJG, Helweg-Larsen J, Matos O, Bretagne S, Cordonnier C (2016) ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 71:2397–2404
Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H (2009) Guideline for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR 58(RR04):1–198
Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P (2016) ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother 71:2405–2413
Wang L, Liang H, Ye L, Jiang J, Liang B, Hunag J (2016) Adjunctive corticosteroids for the treatment of Pneumocystis jiroveci pneumonia in patients with HIV: A meta-analysis. Exp Ther Med 11:683–687
Fujikura Y, Manabe T, Kawana A, Kohno S (2017) Adjunctive corticosteroids for Pneumocystis jirovecii pneumonia in non-HIV-infected patients: A systematic review and meta-analysis of observational studies. Arch Bronconeumol 53:55–61
Kamboj M, Weinstock D, Sepkowitz KA (2006) Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin Infect Dis 43:e92–e94
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Rath, PM. (2019). Clinical Syndromes: Pneumocystis. In: Presterl, E. (eds) Clinically Relevant Mycoses. Springer, Cham. https://doi.org/10.1007/978-3-319-92300-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-92300-0_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92299-7
Online ISBN: 978-3-319-92300-0
eBook Packages: MedicineMedicine (R0)